Is Global Health (MEDANTA) overvalued or fairly valued?

MarketChacha shows Global Health's valuation in context — a forward P/E of about 42.8, a price-to-book of about 9.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Global Health's revenue?

Global Health reported revenue of ₹3,709 Cr for FY2026, with net profit of ₹496 Cr, per official filings.

What is the share price of Global Health (MEDANTA)?

Global Health last traded at ₹1,443.00 (+2.0% on the day), as of 8/18/2026 — a delayed quote shown for education, not investment advice.

Global Health

MEDANTA · NSE · Healthcare · India

Snapshot

TickerMEDANTA

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

HeadquartersGurugram, India

Websitewww.medanta.org

Filings tracked4

About Global Health

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.

Who owns it

Promoters66.4%
Institutions24.6%
Public & other9.0%

70 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.1% → 12.6%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 13% · PAT 14%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,307 Cr

Next fiscal year

Rev ₹6,135 Cr · EPS 33.72

Est. earnings growth +26.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹4,410 Cr

Net margin

12.6%

Revenue CAGR (3y)

+17.9%

Profit CAGR (3y)

+19.5%

Net profit (FY2026)

₹556 Cr

Ask MarketChacha about MEDANTA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹4,410 Cr	₹556 Cr	12.6%
FY2025	₹3,692 Cr	₹481 Cr	13.0%
FY2024	₹3,275 Cr	₹478 Cr	14.6%
FY2023	₹2,694 Cr	₹326 Cr	12.1%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹1,304 Cr	₹159 Cr	12.2%
Q4 FY26	₹1,159 Cr	₹144 Cr	12.4%
Q3 FY26	₹1,121 Cr	₹95 Cr	8.5%
Q2 FY26	₹1,099 Cr	₹158 Cr	14.4%
Q1 FY26	₹1,031 Cr	₹159 Cr	15.4%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Date of payment of Dividend
Intimation under Regulation 30 of Listing Regulations regarding Dividend.
BSE7/31/2026
Investor Presentation
Investor Presentation for First Quarter ended on June 30, 2026, Results of the Company.
BSE7/30/2026
Press Release / Media Release
Press Release for the First Quarter ended June 30, 2026, Results
BSE7/30/2026
Meeting Updates
It is informed that the Nomination & Remuneration Committee in its Meeting held on July 30, 2026, has made a grant of 20,000 ESOPs under GHL LTIP 2024
BSE7/30/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.